TEMPEST THERAPEUTICS INC (TPST)
US87978U1088 - Common Stock
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination...
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Therapeutics Inc. (NASDAQ:TPST) stock is trading higher on Thursday, with a strong session volume of over 23 million as per data from Benzinga Pro. The company entered into an agreement with Roche Holdings AG (OTC:RHHBY) to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a Phase 3 trial for the first-line treatment of liver cancer.
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
The company is preparing for the Phase 3 study start in the first quarter of 2025
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
The company is preparing for the Phase 3 study start in the first quarter of 2025...
Tempest Extends Limited Duration Stockholder Rights Plan
Tempest Extends Limited Duration Stockholder Rights Plan
BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or the “Company”), a clinical-stage...
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study...
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
Expansion of leadership team to strengthen global clinical expertise
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
Expansion of leadership team to strengthen global clinical expertise...
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
Broad agreement on pivotal Phase 3 study plan, including use of current amezalpat dose and scheduleOverall survival, the strongest result from the Phase 2...
TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024
TPST stock results show that Tempest Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma (“HCC”) study demonstrating: Survival...
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday.
Why Is Avrobio (AVRO) Stock Moving Today?
Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today.
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
Tempest Therapeutics stock is up on Thursday with heavy trading of TPST shares ahead of a presentation taking place this morning.